PTCT 株価分析 — PTC Therapeutics Inc (Healthcare >> Biotechnology)
PTCT に関するよくある質問
PTCTのPER(株価収益率)は?
PTC Therapeutics Inc(PTCT)は現在PER 63.03倍で取引されています。
PTCTのROE(自己資本利益率)は?
PTC Therapeutics IncのROEは23.21%です。
PTCTの配当利回りは?
PTC Therapeutics Incの配当利回りは0.00%です。
PTCTの品質スコア(Quality Score)は?
当社のAIはPTCTの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PTCTは今が買い時ですか?
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PTCTはどのセクターに属しますか?
PTC Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
PTCT AI Analysis Summary
Our AI summary for PTCT: PTC Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 63.03, ROE of 23.21%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 68.01
Price
-7.51
(-9.94%)
Day Change
|
|
|---|
PTCT, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1390
|
| Magic Formula Rank by ROE |
1390
|
| Magic Formula Rank by ROIC |
1381
|
| Price | 68.01 |
| PBV / Sector |
-37.88 / 5.20
|
| Earning Per Share | -0.42 |
| PE / Sector |
63.03 / 19.97
|
| PEG or PE/Growth / Sector |
-0.63 / 1.22
|
| Average 1M Daily Value |
108.52 M
GREAT
|
| Average 1W Daily Value |
138.51 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:21 |
| Symbol | PTCT |
| Name | PTC THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 82.95 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6,264.33 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 500 Warren Corporate Center Drive, Warren, NJ, United States, 07059
Phone: 908 222 7000
Website: https://www.ptcbio.com
Employees: 991
Sector: Healthcare >> Biotechnology
Description: PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google